Skip to main content

Drug Interactions between rifabutin and telithromycin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

rifabutin telithromycin

Applies to: rifabutin and telithromycin

GENERALLY AVOID: Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of telithromycin, which is primarily metabolized by the isoenzyme. When telithromycin was given with the potent CYP450 3A4 inducer rifampin in repeated doses, telithromycin peak plasma concentration (Cmax) and systemic exposure (AUC) decreased on average by 79% and 86%, respectively. A similar interaction is expected with other potent CYP450 3A4 inducers such as carbamazepine, enzalutamide, mitotane, phenytoin, phenobarbital, rifabutin, rifapentine and St. John's wort, potentially resulting in subtherapeutic levels of telithromycin and loss of effect. Enzyme activities usually return to normal 14 days after discontinuation of the inducing agent.

MANAGEMENT: Telithromycin should not be used during or within 2 weeks after discontinuation of treatment with a potent CYP450 3A4 inducer.

References (3)
  1. (2004) "Product Information. Ketek (telithromycin)." Aventis Pharmaceuticals
  2. European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products (2004) European Public Assessment Report Ketek (telithromycin) (Rev. 2) http:www.emea.eu.int/humandocs/Humans/EPAR/Ketek/Ketek.htm
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics."

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer